Zai Lab (ZLAB) CLO Edmondson Frazor Titus III Sells 14,600 Shares

Edmondson Frazor Titus III, the Chief Legal Officer of Zai Lab Limited, sold 14,600 shares of the company on June 25, 2026. This transaction did not involve a pre-planned trading program. Shares of Zai Lab Limited, trading under the ticker ZLAB on the NasdaqGM, were priced near $18.0 on Tuesday.

Insider Buying and Selling at Zai Lab Limited

Several insider transactions have taken place at Zai Lab Limited recently. On June 25, 2026, Edmondson Frazor Titus III both bought and sold 14,600 shares, while Dr. Ying Du, the Chairperson and CEO, also bought 58,800 shares. On June 26, 2026, Dr. Du sold 24,543 shares at $17.46 each, and Chief Financial Officer Yajing Chen sold 2,264 shares at the same price.

Zai Lab Limited Stock Down 30.0%

Shares of Zai Lab Limited traded near $18.0 on Tuesday. The company has a market capitalization of approximately $2.03 billion. It operates with a forward P/E ratio of -10.31, reflecting its current lack of profitability. The stock's 52-week range is between $15.96 and $41.2, with a 50-day moving average of $19.52 and a 200-day moving average of $21.50. Zai Lab Limited maintains a current ratio of 2.40 and a quick ratio of 1.84, with a debt-to-equity ratio of 35.03.

Recent Earnings

Zai Lab Limited reported revenue of $453.28 million, with a slight revenue decline of 6.5%. The company's net margin stands at -39.3%, and return on equity is -24.2%, indicating ongoing challenges in profitability. The next earnings report is expected on August 6, 2026.

Analysts Set New Price Targets

Analysts remain optimistic about Zai Lab Limited's prospects. On May 8, 2026, Citigroup maintained a 'buy' rating with a price target of $44. JP Morgan also maintained its 'buy' rating with a target of $32 as of March 18, 2026. The consensus among analysts is a 'buy' recommendation with an average price target of $33.30, based on 12 analyst opinions.

About Zai Lab Limited

Zai Lab Limited is a biopharmaceutical company based in Pudong, China. It focuses on discovering, developing, and commercializing innovative treatments for oncology, immunology, neuroscience, and infectious diseases. The company offers several commercial products, including Zejula for ovarian cancer and VYVGART for myasthenia gravis. Zai Lab collaborates with various global pharmaceutical companies like Pfizer and Amgen. Founded in 2013, it employs around 1,784 people under the leadership of CEO Dr. Ying Du.

Bottom Line

Edmondson Frazor Titus III's recent sale of Zai Lab Limited shares is a notable insider transaction. Investors often track such moves for insights into executive sentiment. It's important to remember that insider transactions are disclosed after completion and may not indicate future actions. Zai Lab's stock performance and analyst ratings continue to be of interest to market watchers.